Treasury Stock

* Reuters is not responsible for the content in this press release.

Mon Mar 31, 2008 8:57am EDT 

  BAGSVAERD, DENMARK, Mar 31 (MARKET WIRE) -- 
 Novo Nordisk A/S - Share repurchase programme

    On 31 January 2008 Novo Nordisk initiated its share repurchase programme in
accordance with the provisions of the European Commission's regulation no
2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

    Under the programme Novo Nordisk will repurchase B shares for an amount of
up to DKK 2 billion in the period from 31 January 2008 to 6 August 2008.

    Since the announcement as of 17 March 2008, the following transactions have
been
made under the programme:


                                Number of      Average      Transaction
                                 shares     purchase price   value, DKK

Accumulated, last announcement  1,657,907                   541,310,698
17 Mar 2008                        50,000      317.7900      15,889,500
18 Mar 2008                        50,000      320.9500      16,047,500
19 Mar 2008                        50,000      323.4900      16,174,500
25 Mar 2008                        50,000      326.1300      16,306,500
26 Mar 2008                        50,000      319.6500      15,982,500
27 Mar 2008                        50,000      318.0200      15,901,000
28 Mar 2008                        50,000      315.6000      15,780,000
Accumulated, 2008               2,007,907                   653,392,198

    
With the transactions stated above, Novo Nordisk owns a total of
26,968,090 treasury shares, corresponding to 4.2% of the share capital. The
total amount of shares in the company is 646,960,000 including treasury shares.

    Novo Nordisk is a healthcare company and a world leader in diabetes care. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significantdifference to patients, the medical profession and society. With
headquarters
in Denmark, Novo Nordisk employs approximately 26,000 employees in 80 countries,
and markets its products in 179 countries. Novo Nordisk's B shares are listed on
the
stock exchanges in Copenhagen and London. Its ADRs are listed on the New
York Stock Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.

    Stock Exchange Announcement no 17 / 2008

    Copyright Copyright Hugin AS 2008. All rights reserved.

    

Further information:

Media:

Outside North America:
Elin K Hansen
Tel: (+45) 4442 3450
Email Contact

In North America:
Sean Clements
Tel: (+1) 609 514 8316
Email Contact

Investors:

Outside North America:
Mads Veggerby Lausten
Tel: (+45) 4443 7919
Email Contact

Hans Rommer
Tel: (+45) 4442 4765
Email Contact

In North America:
Christian Qvist Frandsen
Tel: (+1) 609 919 7937
Email Contact

Copyright 2008, Market Wire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.